Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03491423
Other study ID # HANNEQUIN APPARA 2016
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 4, 2018
Est. completion date May 3, 2019

Study information

Verified date September 2019
Source Centre Hospitalier Universitaire Dijon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recommendations for cardiovascular rehabilitation (CVR) encourage exercise training, primarily involving the aerobic system, to allow patients to regain independence in daily activities. However, the lactic anaerobic process is also involved during these activities (stair climbing, carrying loads, etc.). Hence there is a major interest in accurately assessing patients' anaerobic capacities in order to tailor suitable exercise programs. However, there are no functional tests specifically dedicated to the evaluation of lactic anaerobic metabolism and adapted to people with coronary disease. The investigators offer a dedicated test, the short and fast test (SFST), which can be applied in current clinical practice and has already been evaluated in a population of healthy subjects. The purpose of this project is to evaluate the safety, feasibility and validity of SFST in a population of patients with coronary artery disease.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date May 3, 2019
Est. primary completion date May 3, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient who has given oral consent Adult patient (male or female) with coronary artery disease without heart failure referred for rehabilitation program Left ventricular ejection fraction (Simpson method) > 45%.

Exclusion Criteria:

- Protected adult

- Patient not affiliated to a national health insurance scheme

- Pregnant or breastfeeding woman

- Orthostatic hypotension

- Severe obstructive heart disease

- aortic valve narrowing

- Progressive severe cardiac rhythm or conduction disorders not requiring a device, detected during the initial stress test.

- intracavitary cardiac thrombus

- severe pulmonary arterial hypertension (systolic pulmonary hypertension >70mmHg)

- recent venous thromboembolic history (last 3 months)

- heart transplantation

- associated medical condition that can predominantly impair functional and respiratory capacities (examples: unstabilized metabolic disorders such as progressive renal failure, significant asthenia related to a severe unstabilized condition such as neoplasia, systemic disease, chronic obstructive pulmonary disease...)

- physical impairments of the lower limbs hindering the test, whether neurological (central or peripheral), arterial (in particular, arteriopathy of the lower limbs with systolic index < 0.6) or orthopedic (degenerative or inflammatory rheumatism)

- Treatment with Corticosteroids, Anabolics, or L-Carnitine.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Short and fast step test without measurement of pulmonary gas exchange
For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
Biological:
glucose meter
glucose meter to measure lactatemia
Other:
ECG / heart rate
ECG and heart rate (HR) collection by telemetry
questionnaires
VAS pain assessment and evaluation of effort perception according to Borg's scale
Short and fast step test with measurement of pulmonary gas exchange
For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.

Locations

Country Name City State
France CHU de DIJON Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary percentage of patients who completed the SFST without complications - Absence of muscular or bone-joint disorders quantified according to the VAS. The exercise will be considered as not tolerated if pain is reported during the test and/or at day 3 (VAS=6).
AND no falls or stumbling related trauma
AND absence of cardiovascular or blood pressure events:
Hypertension (systolic pressure greater than 250 mmHg (O'Brien et al. 2005) or hypotension with clinical consequences (malaise or feeling unwell)
Discomfort, chest pain, onset of vascular claudication
Rhythm or conduction disorders or repolarization abnormalities, at a higher frequency than that observed in the pre-inclusion stress test
Abnormal increase in heart rate (greater than the maximum rate determined during the stress test).
through study completion, an average of 11 days